Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014;122:231–66. https://doi.org/10.1016/b978-0-444-52001-2.00010-8.

Article  PubMed  Google Scholar 

von Büdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol. 2015;73(3–4):238–46. https://doi.org/10.1159/000377675.

Article  CAS  Google Scholar 

Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, et al. Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther. 2009;9(7):889–95. https://doi.org/10.1517/14712590903018837.

Article  CAS  PubMed  Google Scholar 

van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010;47(2):199–210. https://doi.org/10.1053/j.seminhematol.2010.01.007.

Article  CAS  PubMed  Google Scholar 

Schnueriger A, Grau R, Sondermann P, Schreitmueller T, Marti S, Zocher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol. 2011;48(12–13):1512–7. https://doi.org/10.1016/j.molimm.2011.04.010.

Article  CAS  PubMed  Google Scholar 

Cheng ZJ, Garvin D, Paguio A, Moravec R, Engel L, Fan F, et al. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. J Immunol Methods. 2014;414:69–81. https://doi.org/10.1016/j.jim.2014.07.010.

Article  CAS  PubMed  Google Scholar 

Wu Y, Li JJ, Kim HJ, Liu X, Liu W, Akhgar A, et al. A neutralizing antibody assay based on a reporter of antibody-dependent cell-mediated cytotoxicity. AAPS J. 2015;17(6):1417–26. https://doi.org/10.1208/s12248-015-9798-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, et al. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. Sci Rep. 2016;6:19772. https://doi.org/10.1038/srep19772.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung S, Nguyen V, Lin YL, Kamen L, Song A. Thaw-and-use target cells pre-labeled with calcein AM for antibody-dependent cell-mediated cytotoxicity assays. J Immunol Methods. 2017;447:37–46. https://doi.org/10.1016/j.jim.2017.04.005.

Article  CAS  PubMed  Google Scholar 

Pharmacopeia US. Immunogenicity assays—design and validation of assays to detect anti-drug neutralizing antibody. 2023;General Chapter(1106.1). https://doi.org/10.31003/USPNF_M8546_01_01.

Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods. 2007;321(1–2):1–18. https://doi.org/10.1016/j.jim.2006.12.004.

Article  CAS  PubMed  Google Scholar 

Wu B, Chung S, Jiang XR, McNally J, Pedras-Vasconcelos J, Pillutla R, et al. Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics. Aaps j. 2016;18(6):1335–50. https://doi.org/10.1208/s12248-016-9954-6.

Article  CAS  PubMed  Google Scholar 

Guideline on Immunogenicity assessment of therapeutic proteins. EMEA/CHMP/BMWP/14327/2006 Rev 1 ed: European Medicines Agency; 2017.

Immunogenicity testing of therapeutic protein products —developing and validating assays for anti-drug antibody detection. In: U.S. Department of Health and Human Services FDA, editor. 2019.

Horowitz D. Draft guidance for industry on assay development for immunogenicity testing of therapeutic proteins. In: Services DoHaH, editor. Federal Register 2009. p. 63758.

Gupta S, Devanarayan V, Finco D, Gunn GR 3rd, Kirshner S, Richards S, et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011;55(5):878–88. https://doi.org/10.1016/j.jpba.2011.03.038.

Article  CAS  PubMed  Google Scholar 

Zhang T, Chen H, Shao W, Lin Z, Melhem M, Lu S, et al. A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open. 2021;7:8. https://doi.org/10.1186/s41120-021-00039-w.

Article  Google Scholar 

Ablamunits V, Basak S, Henderson R, Caiazzo T, Kamerud J, et al. A competitive ligand-binding assay to detect neutralizing antibodies to a bispecific drug using a multiplex Meso Scale Discovery platform. Bioanalysis. 2021;13(22):1659–69. https://doi.org/10.4155/bio-2021-0177.

Article  CAS  PubMed  Google Scholar